CORCEPT-CORT125134-557-BELLA
Phase II
OPEN TO ACCRUAL
An Open-Label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination with Different Treatment Regimens in Patients with Gynecological Cancers (BELLA)
GOG-3082-ACRIVON-ACR-368-201
Phase I/II
OPEN TO ACCRUAL
A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status
GOG-3096-DAIICHI-DS6000-109
Phase II/III
OPEN TO ACCRUAL
A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-Directed Antibody-Drug Conjugate, in Subjects with Platinum-Resistant, High-Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
REGENERON-R4018-ONC-2445
Phase II
OPEN TO ACCRUAL
Multi-Arm Phase 2 Study Of Ubamatamab (Regn4018; Muc16×Cd3 Bispecific Antibody) With Or Without Additional Agents In Platinum - Resistant Ovarian Cancer